INVESCO LTD (IVZ)
BMG491BT1088 - Common Stock
Overall IVZ gets a fundamental rating of 4 out of 10. We evaluated IVZ against 220 industry peers in the Capital Markets industry. Both the profitability and financial health of IVZ have multiple concerns. IVZ is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
IVZ had positive earnings in the past year.
IVZ had a positive operating cash flow in the past year.
IVZ had positive earnings in 4 of the past 5 years.
IVZ had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IVZ has a worse Return On Assets (-1.50%) than 83.87% of its industry peers.
IVZ's Return On Equity of -2.80% is on the low side compared to the rest of the industry. IVZ is outperformed by 80.65% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.04%, IVZ is doing worse than 66.36% of the companies in the same industry.
IVZ had an Average Return On Invested Capital over the past 3 years of 3.52%. This is below the industry average of 6.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.5% | ||
| ROE | -2.8% | ||
| ROIC | 2.04% |
ROA(3y)1.8%
ROA(5y)1.66%
ROE(3y)3.73%
ROE(5y)3.79%
ROIC(3y)3.52%
ROIC(5y)3.73%
1.3 Margins
IVZ's Operating Margin of 11.78% is on the low side compared to the rest of the industry. IVZ is outperformed by 70.05% of its industry peers.
In the last couple of years the Operating Margin of IVZ has declined.
The Gross Margin of IVZ (66.74%) is better than 65.44% of its industry peers.
In the last couple of years the Gross Margin of IVZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.78% | ||
| PM (TTM) | N/A | ||
| GM | 66.74% |
OM growth 3Y-11.2%
OM growth 5Y-9.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.48%
2. Health
2.1 Basic Checks
Compared to 1 year ago, IVZ has less shares outstanding
IVZ has more shares outstanding than it did 5 years ago.
IVZ has a worse debt/assets ratio than last year.
2.2 Solvency
IVZ has an Altman-Z score of 1.00. This is a bad value and indicates that IVZ is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.00, IVZ perfoms like the industry average, outperforming 52.53% of the companies in the same industry.
IVZ has a debt to FCF ratio of 5.07. This is a neutral value as IVZ would need 5.07 years to pay back of all of its debts.
The Debt to FCF ratio of IVZ (5.07) is better than 62.67% of its industry peers.
A Debt/Equity ratio of 0.51 indicates that IVZ is somewhat dependend on debt financing.
IVZ's Debt to Equity ratio of 0.51 is fine compared to the rest of the industry. IVZ outperforms 69.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 1 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
IVZ has a Current Ratio of 0.75. This is a bad value and indicates that IVZ is not financially healthy enough and could expect problems in meeting its short term obligations.
IVZ has a Current ratio of 0.75. This is in the lower half of the industry: IVZ underperforms 63.59% of its industry peers.
A Quick Ratio of 0.75 indicates that IVZ may have some problems paying its short term obligations.
IVZ's Quick ratio of 0.75 is on the low side compared to the rest of the industry. IVZ is outperformed by 63.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.78% over the past year.
Measured over the past years, IVZ shows a decrease in Earnings Per Share. The EPS has been decreasing by -9.08% on average per year.
The Revenue has been growing slightly by 2.45% in the past year.
Measured over the past years, IVZ shows a small growth in Revenue. The Revenue has been growing by 1.47% on average per year.
EPS 1Y (TTM)16.78%
EPS 3Y-8.01%
EPS 5Y-9.08%
EPS Q2Q%25.71%
Revenue 1Y (TTM)2.45%
Revenue growth 3Y-2.38%
Revenue growth 5Y1.47%
Sales Q2Q%0.56%
3.2 Future
The Earnings Per Share is expected to grow by 6.10% on average over the next years.
Based on estimates for the next years, IVZ will show a small growth in Revenue. The Revenue will grow by 3.76% on average per year.
EPS Next Y12.16%
EPS Next 2Y12.35%
EPS Next 3Y12.08%
EPS Next 5Y6.1%
Revenue Next Year0.52%
Revenue Next 2Y3.26%
Revenue Next 3Y3.76%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.63, which indicates a very decent valuation of IVZ.
Compared to the rest of the industry, the Price/Earnings ratio of IVZ indicates a somewhat cheap valuation: IVZ is cheaper than 67.28% of the companies listed in the same industry.
IVZ is valuated cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.31, which indicates a very decent valuation of IVZ.
Based on the Price/Forward Earnings ratio, IVZ is valued a bit cheaper than 73.27% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.99, IVZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.63 | ||
| Fwd PE | 9.31 |
4.2 Price Multiples
IVZ's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IVZ is cheaper than 73.73% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IVZ is valued cheaply inside the industry as 80.65% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.42 | ||
| EV/EBITDA | 16.43 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IVZ's earnings are expected to grow with 12.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.87
PEG (5Y)N/A
EPS Next 2Y12.35%
EPS Next 3Y12.08%
5. Dividend
5.1 Amount
IVZ has a Yearly Dividend Yield of 4.89%, which is a nice return.
IVZ's Dividend Yield is comparable with the industry average which is at 9.57.
IVZ's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
5.2 History
The dividend of IVZ has a limited annual growth rate of 1.50%.
IVZ has been paying a dividend for at least 10 years, so it has a reliable track record.
IVZ has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.5%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
IVZ has negative earnings and hence a negative payout ratio. The dividend may be in danger.
IVZ's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP-146.45%
EPS Next 2Y12.35%
EPS Next 3Y12.08%
INVESCO LTD
NYSE:IVZ (12/24/2024, 8:22:04 PM)
After market: 17.75 0 (0%)17.75
+0.27 (+1.54%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners89.71%
Inst Owner Change28.07%
Ins Owners0.68%
Ins Owner Change0.19%
Market Cap7.98B
Analysts66.67
Price Target19.64 (10.65%)
Short Float %2.59%
Short Ratio2.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
Dividend Growth(5Y)1.5%
DP-146.45%
Div Incr Years3
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.75%
Min EPS beat(2)1.96%
Max EPS beat(2)7.53%
EPS beat(4)3
Avg EPS beat(4)1.89%
Min EPS beat(4)-18.24%
Max EPS beat(4)16.32%
EPS beat(8)5
Avg EPS beat(8)-0.93%
EPS beat(12)6
Avg EPS beat(12)-4.14%
EPS beat(16)10
Avg EPS beat(16)-0.14%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-1.23%
Revenue beat(4)0
Avg Revenue beat(4)-3.47%
Min Revenue beat(4)-7.11%
Max Revenue beat(4)-1.23%
Revenue beat(8)2
Avg Revenue beat(8)5.23%
Revenue beat(12)6
Avg Revenue beat(12)12.47%
Revenue beat(16)10
Avg Revenue beat(16)17.91%
PT rev (1m)5.19%
PT rev (3m)10%
EPS NQ rev (1m)-0.15%
EPS NQ rev (3m)4.5%
EPS NY rev (1m)0.09%
EPS NY rev (3m)3.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.3%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.63 | ||
| Fwd PE | 9.31 | ||
| P/S | 1.36 | ||
| P/FCF | 5.42 | ||
| P/OCF | 5.03 | ||
| P/B | 0.54 | ||
| P/tB | 38.5 | ||
| EV/EBITDA | 16.43 |
EPS(TTM)1.67
EY9.41%
EPS(NY)1.91
Fwd EY10.74%
FCF(TTM)3.27
FCFY18.44%
OCF(TTM)3.53
OCFY19.9%
SpS13.1
BVpS32.83
TBVpS0.46
PEG (NY)0.87
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.5% | ||
| ROE | -2.8% | ||
| ROCE | 2.76% | ||
| ROIC | 2.04% | ||
| ROICexc | 2.13% | ||
| ROICexgc | 6.61% | ||
| OM | 11.78% | ||
| PM (TTM) | N/A | ||
| GM | 66.74% | ||
| FCFM | 24.99% |
ROA(3y)1.8%
ROA(5y)1.66%
ROE(3y)3.73%
ROE(5y)3.79%
ROIC(3y)3.52%
ROIC(5y)3.73%
ROICexc(3y)3.74%
ROICexc(5y)3.94%
ROICexgc(3y)11.91%
ROICexgc(5y)N/A
ROCE(3y)4.75%
ROCE(5y)5.03%
ROICexcg growth 3Y-95.79%
ROICexcg growth 5YN/A
ROICexc growth 3Y-13.73%
ROICexc growth 5Y-15.78%
OM growth 3Y-11.2%
OM growth 5Y-9.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.48%
F-Score5
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 8.51 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 181.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 1 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)80.55%
Cap/Depr(5y)73.63%
Cap/Sales(3y)2.55%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.78%
EPS 3Y-8.01%
EPS 5Y-9.08%
EPS Q2Q%25.71%
EPS Next Y12.16%
EPS Next 2Y12.35%
EPS Next 3Y12.08%
EPS Next 5Y6.1%
Revenue 1Y (TTM)2.45%
Revenue growth 3Y-2.38%
Revenue growth 5Y1.47%
Sales Q2Q%0.56%
Revenue Next Year0.52%
Revenue Next 2Y3.26%
Revenue Next 3Y3.76%
Revenue Next 5YN/A
EBIT growth 1Y-24.13%
EBIT growth 3Y-13.32%
EBIT growth 5Y-8.6%
EBIT Next Year21.17%
EBIT Next 3Y9.44%
EBIT Next 5Y5.12%
FCF growth 1Y1547.26%
FCF growth 3Y0.46%
FCF growth 5Y14.06%
OCF growth 1Y548.71%
OCF growth 3Y1.72%
OCF growth 5Y13.48%